# DESCRIPTION

## BACKGROUND OF THE INVENTION

- relate to recombinant DNA technology
- describe alphavirus genus
- identify need for melanoma treatment

## BRIEF SUMMARY OF THE INVENTION

- enhance immune response to melanoma antigen
- provide methods for preventing melanoma
- describe pharmaceutical composition

## DETAILED DESCRIPTION OF THE INVENTION

- motivate need for melanoma treatment
- introduce RNA replicon vector system
- describe immunization protocols
- discuss melanocyte differentiation antigens
- describe use of alphavirus replicon vector system
- discuss immunogenic protein and TRP2
- summarize efficacy of VEE VRP compositions
- describe surprising ability of TRP2 immune response
- discuss role of humoral responses and CD8+ T-cell response
- describe heterologous prime-boost immunization strategy
- illustrate need for improvements in melanoma treatment
- define abbreviations
- define alphavirus terms
- describe 5' and 3' alphavirus replication recognition sequences
- define minimal 5' alphavirus replication recognition sequence
- describe alphavirus RNA replicon
- define helper and helper construct
- describe helper cell and packaging cell
- define alphavirus replicon particles
- describe promoter for directing transcription
- describe transcription regulatory sequence
- describe IRES element
- define amino acid abbreviations
- describe expression directed by a sequence
- define alphavirus-permissive cells
- describe structural protein and alphavirus structural protein
- describe distribution of structural proteins among helper nucleic acid molecules
- describe deletion of structural proteins from replicon RNA
- define replication defective
- describe helper cell requirements
- define alphavirus structural proteins
- outline RNA helper constructs
- describe introduction of RNA helpers into cells
- discuss single DNA molecule alternative
- introduce attenuating mutations
- describe methods for identifying attenuating mutations
- outline specific attenuating mutations for VEE
- outline specific attenuating mutations for S.A. AR86
- describe site-directed mutagenesis
- introduce alphavirus replicon vector
- describe preparation of infective ARPs
- define TRP2 protein
- describe human melanoma antigen sequences
- discuss synonymous sequences and allelic variations
- outline standard techniques for cloning and DNA manipulation
- describe pharmaceutical formulations
- outline administration methods
- describe vaccine composition
- list adjuvants
- discuss dosage and administration
- explain multiple dose schedules
- incorporate references by reference
- disclaim prior art
- describe VRP formulations
- define terms and expressions
- discuss modifications and variations
- choose formulation and administration
- discuss treatment strategies
- formulate and administer compositions
- manufacture pharmaceutical compositions

### Murine TRP-2 Cloning

- clone murine TRP-2 gene

### Replicon Production

- generate pERK3-murine TRP-2 replicon vector

### VRP Production

- package TRP2-expressing replicon into VRP

### Human TRP-2 Viral Replicon Particles

- generate human TRP-2 expressing VRPs

### Mice and Cell Lines.

- describe mouse strains and cell lines used
- outline vaccination and tumor challenge protocols

### ELISPOT and T-Cell Assays

- measure T cell response to TRP2-specific peptides

### ELISA

- detect TRP2-specific IgGs in mouse sera

### Analysis of the Tumor Infiltrate

- analyze tumor infiltrating immune cells

